USPTO serial 88221611
ERP
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 25, 2020
- Examiner
- MEYERS, MORGAN LAURA
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ERP?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $425
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Mononuclear Therapeutics Limited
Shatin NT, HK
Mononuclear Therapeutics Limited
Shatin NT, HK
Mononuclear Therapeutics Limited
Shatin NT, HK
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Charles J. Meyer
Charles J. Meyer Woodard, Emhardt, Henry, Reeves & Wagner, LLP111 Monument Circle, Suite 3700Indianapolis, IN 46204-5137United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for medical purposes for blood system disorders, cardiac disorders, connective tissue disorders, endocrine disorders, immune system disorders, metabolism and nutrition disorders, neoplasms, nervous system disorders, pregnancy, puerperium and perinatal disorders, skin and subcutaneous tissue disorders, vascular disorders; plasma for treatment of blood system disorders, cardiac disorders, connective tissue disorders, endocrine disorders, immune system disorders, metabolism and nutrition disorders, neoplasms, nervous system disorders, pregnancy, puerperium and perinatal disorders, skin and subcutaneous tissue disorders, vascular disorders; diagnostic and therapeutic preparations for medical or veterinary use, in particular preparations produced using molecular biological, biotechnological and genetic methods; surgical implants grown from stem cells; stem cells for medical purposes; pharmaceutical preparations for stem cell transplantation, therapy and research; pharmaceutical and veterinary preparations for treatment of blood system disorders, cardiac disorders, connective tissue disorders, endocrine disorders, immune system disorders, metabolism and nutrition disorders, neoplasms, nervous system disorders, pregnancy, puerperium and perinatal disorders, skin and subcutaneous tissue disorders, vascular disorders; sanitary preparations for medical purposes; blood plasma; reagents for medical purposes; medical diagnostic reagent; biological preparations for medical purposes used in the treatment of blood system disorders, cardiac disorders, connective tissue disorders, endocrine disorders, immune system disorders, metabolism and nutrition disorders, neoplasms, nervous system disorders, pregnancy, puerperium and perinatal disorders, skin and subcutaneous tissue disorders, vascular disorders; chemical preparations for pharmaceutical purposes, namely, chemical preparations for blood system disorders, cardiac disorders, connective tissue disorders, endocrine disorders, immune system disorders, metabolism and nutrition disorders, neoplasms, nervous system disorders, pregnancy, puerperium and perinatal disorders, skin and subcutaneous tissue disorders, vascular disorders; diagnostic preparations for medical purposes; pharmaceutical products for the treatment of blood system disorders, cardiac disorders, connective tissue disorders, endocrine disorders, immune system disorders, metabolism and nutrition disorders, neoplasms, nervous system disorders, pregnancy, puerperium and perinatal disorders, skin and subcutaneous tissue disorders, vascular disorders | ACTIVE | Nov 1, 2019 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Mononuclear Therapeutics Limited
- Other trademarks owned by Mononuclear Therapeutics Limited
- Other trademarks owned by Mononuclear Therapeutics Limited
- Other trademarks in Class 005
- Similar marks named ERP
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 9, 2026 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Sep 9, 2026 | 8.OK | REGISTERED - SEC. 8 (6-YR) ACCEPTED | The USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline. |
| Sep 7, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 7, 2026 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Aug 25, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Dec 22, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 22, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 22, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 25, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 23, 2020 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jul 22, 2020 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jul 2, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 1, 2020 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jul 1, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 1, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 17, 2020 | IUAF | USE AMENDMENT FILED | — |
| Jun 17, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 17, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 17, 2020 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 29, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 29, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 17, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 22, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 22, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 2, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 25, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 25, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 18, 2019 | ALIE | ASSIGNED TO LIE | — |
| Sep 14, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 13, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 12, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 12, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 13, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 13, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 13, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 31, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 11, 2018 | NWAP | NEW APPLICATION ENTERED | — |